Will Roche/Genentech team create industry model?

Roche's proposal to acquire all outstanding shares of Genentech is being viewed as a model marriage of a Big Pharma company focused on molecular diagnostics and a Big Biotech company designing new genetic therapies for an era of personalized medications.

The $43.7 billion offer is seen as a bold move by Roche's new CEO, Severin Schwan (photo). And Schwan is insisting that the offer has nothing to do with finding ways to bolster profits through cost-cutting maneuvers.

"Now is a good time to take Genentech private,'" Schwan told BusinessWeek in a telephone interview. "This transaction is about strengthening innovation; it is not about cost-cutting."  

- read the article from BusinessWeek

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.